H.R. 10628 explained · 119th Congress · Pending in Congress
Biosimilars Access and Affordability Act
Cosponsors: 8 (5 D, 3 R) · per Congress.gov, 2026-10-14
Introduced: 2026-09-28
Latest action (2026-09-28): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
What H.R. 10628 does, in plain terms
The Congressional Research Service has not published a summary of H.R. 10628 yet. Its official title: “Biosimilars Access and Affordability Act”.
Constitution Index
“VFA Constitution grade”
Not graded yet
H.R. 10628 has not been graded yet. New measures with an official summary are graded daily under the published rubric.
What should pass
“VFA SI Solution”
No solution yet
A sourced SI draft appears here once it passes automated checks (Constitution citation, source verification, independent SI critic). How publication works.
For journalists and bloggers
“Embed this grade”
Free to use with the link back. The badge and card update when the grade changes. Embed terms →
